Law firms recently have started taking inquires from people who may have a potential yasmin lawsuit due to injury from side effects.
The FDA issued a letter to Bayer AG and strongly suggested that they talk about the numerous side effects. The FDA felt that the ads were misleading These claims are misleading because they suggest that Yasmin’s “different kind of hormone” offers unique “chemistry” benefits and that this difference contributes to the high rate of drug efficacy.
Yasmin is a type of birth control pill marketed and manufactured by the German company Bayer Schering Pharma AG Yasmin first entered the American market in 2001 and has generated close to 500 million in sales to date.Yasmin is an oral contraceptive and is a synthetic spironolactone analogue known in the medical world as drospirenone.
Drospirenone binds to the progesterone receptor, the resulting complex becomes activated and binds to specific sites on DNA. This leads to an increased difficulty of sperm entry into the uterus and implantation.
When the Yasmin TV advertising started the FDA took issue with the television commercials which featured women discussing the benefits of the product. The ads had a music score and dialog between the actors.
While there has been no official Yasmin recall, the U.S. Food and Drug Administration (FDA) has warned Bayer AG that the advertising campaign for Yasmin and Yaz were misleading, namely that the ads suggested a broad useage of the medication, minimized potentially serious side effects, and overstated the efficacy of the pill.
Twice have letters been sent to Bayer AG, and once has Bayer AG been ordered to correct its ads, costing the company a total of $20 million. Bayer AG is also under obligation to submit future ad campaigns to the FDA for approval before it launches them in the U.S.